Up to date March 31, 2021 at 8:17 a.m.ET

New medical trials have proven that Pfizer’s COVID-19 vaccine elicits “100% efficacy and sturdy antibody responses” in adolescents 12 to fifteen years previous, the pharmaceutical firm stated on Wednesday. The trial included 2,260 trial members; the outcomes are even higher than earlier responses from members aged 16 to 25.

Pfizer and its vaccine accomplice BioNTech say they’ll submit the outcomes “as quickly as doable” to the US Meals and Drug Administration and the European Medicines Company, asking regulators to increase their authorizations for using the vaccine in sufferers. youth.

Pfizer will submit the information “within the coming weeks,” Pfizer CEO and Chairman Albert Bourla stated in a press launch on the lawsuit. Calling the outcomes encouraging, he added that the corporate was performing “with the hope of beginning to vaccinate this age group earlier than the following college 12 months”.

Through the medical trial, 18 individuals within the placebo group developed COVID-19, whereas none within the vaccinated group did. Blood assessments confirmed a powerful immune system response a month after members obtained the second dose of the vaccine, in line with a summary of test data printed by Pfizer.

Relating to potential unwanted effects, Pfizer stated the vaccine was properly tolerated within the Section 3 trial.

At present, the Pfizer-BioNTech vaccine is simply authorised for people who find themselves at the very least 16 years of age. The businesses that developed the vaccine collectively are working to check it in kids as younger as 6 months previous. Within the first a part of this examine, a gaggle of kids aged 5 to 11 obtained their first vaccines final week. A second group of kids, aged 2 to five, are anticipated to obtain their first doses subsequent week.